INSP stock forecast, quote, news & analysis
Inspire Medical Systems Inc operates as a medical technology company... Show more
Inspire Medical Systems (INSP) Stock Analysis: Rebuilding Growth Through Reimbursement Turbulence
Key Takeaways
- Inspire Medical Systems (INSP) has traded in a relatively tight range over the past month, closing near $71 after gaining roughly 3% from late September levels.
- The company is the established leader in implantable hypoglossal nerve stimulation (HNS) therapy for moderate-to-severe obstructive sleep apnea (OSA).
- Coding and reimbursement disruptions tied to the Inspire V system and the WISeR prior-authorization program have weighed on near-term revenue visibility.
- Second-quarter 2026 results beat expectations, returning the company to GAAP profitability, and management raised its full-year 2026 outlook.
- The Project Horizon restructuring is designed to free up approximately $30 million in annualized investment capacity to rebuild patient flow.
- Longer-term, the investment case rests on penetration of a large, undertreated OSA population and a growing body of cardiovascular outcomes data.
- For additional detail, review INSP Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated trading systems are positioned across the market.
Current Market Snapshot
INSP shares have been consolidating after a period of volatility, holding near $71 after a modest gain of about 3% over the trailing month. The stock has recovered meaningfully from the high-$50s to low-$60s range it traded in around the company's second-quarter report, reflecting improving investor sentiment as reimbursement uncertainty has begun to moderate. The move remains below the 10% threshold that typically signals a sharp momentum shift, suggesting the market is waiting for clearer evidence of a revenue inflection before re-rating the shares.
Inspire Medical Systems (INSP) Business Overview and Competitive Position
Inspire Medical Systems is a medical technology company focused on the treatment of obstructive sleep apnea. Its flagship Inspire therapy is the first and only FDA-approved implantable neurostimulation system for moderate-to-severe OSA, providing a surgically implanted alternative for patients who cannot tolerate or benefit from continuous positive airway pressure (CPAP). The device stimulates the hypoglossal nerve to maintain an open airway during sleep.
Founded in 2007 and headquartered in Golden Valley, Minnesota, the company has treated more than 140,000 patients since inception. Its current-generation Inspire V system features accelerometer-based sensing technology, with an Inspire VI platform in development. As the pioneer in hypoglossal nerve stimulation, Inspire holds a leading position in its category, though competition has emerged from players such as LivaNova (LIVN) and Nyxoah (NYXH).
Recent Developments Driving INSP
The dominant theme for Inspire in 2026 has been reimbursement disruption rather than demand fundamentals. Changes to coding for the Inspire V procedure and the rollout of the WISeR program — a government initiative applying AI-reviewed prior authorization to Medicare cases in six pilot states — slowed prior-authorization submissions and delayed procedures. Management estimated these factors reduced first-quarter revenue by roughly $20 million and second-quarter revenue by approximately $40 million, with a full-year impact projected at $120 million to $130 million.
Despite the headwinds, second-quarter 2026 results came in ahead of consensus. Revenue of $200.6 million, while down 7.6% year over year, beat estimates near $195 million, and adjusted diluted EPS of $0.14 compared favorably with an expected loss. The company returned to GAAP profitability and raised its full-year 2026 guidance to $835 million to $875 million in revenue, with adjusted operating margin of 4% to 6% and adjusted EPS of $1.05 to $1.45.
The company also announced Project Horizon, an organizational and supply-chain optimization expected to create $30 million in annualized growth investment capacity, alongside $20 million to $25 million in pretax restructuring charges. Meanwhile, CMS proposed increases to 2027 hospital outpatient (up 12%) and ambulatory surgery center (up 15%) reimbursement for the Inspire V procedure, and the company is pursuing a new Category 1 CPT code for its single-lead system targeted for January 2028. Following the results, analysts issued a mix of upgrades and price-target increases, including an upgrade from Oppenheimer with an $85 target.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems from a broader universe of hundreds of AI-driven bots that trade thousands of tickers. Only the top-performing and most relevant strategies are featured, giving traders a focused view of currently active approaches. The bots vary in strategy, holding timeframe, and performance metrics, so users can compare systems that align with their own objectives and risk tolerance. For investors monitoring names like Inspire Medical Systems, the page offers a way to observe how quantitative, AI-based strategies are responding to evolving market conditions.
2026 Outlook and What Investors Should Watch
Inspire's near-term trajectory hinges on how quickly coding clarity translates into normalized prior-authorization and procedure volumes. Management has guided third-quarter revenue down 8% to 10% year over year, with roughly breakeven adjusted operating income, while signaling sequential improvement into the fourth quarter as providers gain confidence in billing practices.
Key items to monitor include the third-quarter earnings report, the final 2027 CMS reimbursement rates published in November, and the outcome of the revised CPT code application. Investors should also track the evolving WISeR rollout, the competitive landscape in hypoglossal nerve stimulation, and the interplay between GLP-1 weight-loss therapies and OSA patient flow. The expanding body of clinical data linking Inspire therapy to improved cardiovascular outcomes remains a longer-term catalyst for both physician adoption and payer coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INSP sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for INSP moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for INSP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
INSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In 67 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
INSP moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. INSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.168) is normal, around the industry mean (4.170). P/E Ratio (13.486) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.375) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices